抗血浆抑制物的凝血因子IXa变体在体内增强血栓形成
研究通过改造凝血因子IXa(FIXa)使其对血浆抑制物(如抗凝血酶AT)反应性改变,同时保持与辅因子FVIIIa结合后的促凝功能。在血友病B小鼠中,延迟FIXa抑制可显著减轻出血表型并促进血栓形成,提示调控FIXa抑制对血管损伤部位凝血的空间和时间控制起重要作用。
要点
- FIXa变体(如FIXa-V16L)因部分抗AT抑制而具有延长的血浆活性半衰期。
- 在血友病B小鼠中,延迟FIXa抑制可减轻出血表型并促进血栓形成。
- 改变FIXa抑制可能具有治疗获益。
核心结论
- FIXa抑制的调控对血管损伤部位凝血的空间和时间控制起主要作用。
- 改变FIXa抑制可能具有治疗获益。
研究设计与样本
- 研究生成对血浆抑制物反应性改变的FIXa变体,并在血友病B小鼠中进行体内研究。
主要发现
- 选定的FIXa变体(如FIXa-V16L)因部分抗AT抑制而具有延长的血浆活性半衰期。
- 在血友病B小鼠中,延迟FIXa抑制对减轻出血表型和在给予FIX蛋白后促进血栓形成有重大影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factor IXa (FIXa) plays a pivotal role in coagulation by contributing to FX activation via the intrinsic pathway. Although antithrombin (AT) and other plasma inhibitors are thought to regulate FIXa procoagulant function, the impact of FIXa inhibition on thrombin generation and clot formation in vivo remains unclear. Here, we generated FIXa variants with altered reactivity to plasma inhibitors that target the FIXa active site but maintain procoagulant function when bound to its cofactor, FVIIIa. We found that selected FIXa variants (eg, FIXa-V16L) have a prolonged activity half-life in the plasma due, in part, to AT resistance. Studies using hemophilia B mice have shown that delayed FIXa inhibition has a major impact on reducing the bleeding phenotype and promoting thrombus formation following administration of FIX protein. Overall, these results demonstrate that the regulation of FIXa inhibition contributes in a major way to the spatial and temporal control of coagulation at the site of vascular injury. Our findings provide novel insights into the physiological regulation of FIXa, enhance our understanding of thrombus formation in vivo via the intrinsic pathway, and suggest that altering FIXa inhibition could have therapeutic benefits.
引用
- Ivanciu L, Arruda VR, Camire RM, et al. Factor IXa variants resistant to plasma inhibitors enhance clot formation in vivo. Blood. 2023. PMID: 36724452. doi:10.1182/blood.2022018083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。